RxDoctor Payments Data

Michael Limberg, MD

Ophthalmology · San Luis Obispo, CANPI 1063569655

Payments from drug & device makers

$3,427in general payments, 2019–2025

Across 92 payments — averaging $37.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Revance Therapeutics, Inc.$561
  • Johnson & Johnson Surgical Vision, Inc.$246
  • Merz North America, Inc.$195
  • NEW World Medical,inc.$84
  • Rxsight Inc$39
  • plus $122 from 6 others

What the payments were for

  • Speaking & faculty fees$42112%
  • Food & beverage$2,97387%
  • Education$140%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,427 in reported general payments places this provider in the 65th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$807,481
Medicare patients
838
Services billed
9,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate18$10,033
Tobramycin-DexamethasoneTobramycin/Dexamethasone188$6,528
Cyclosporine12$5,298
Travoprost18$3,593
Loteprednol Etabonate19$2,992
Prednisolone Acetate70$2,674
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$2,264
Ketorolac Tromethamine131$1,617
Latanoprost141$1,516
Brimonidine Tartrate43$815
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat43$763
Timolol Maleate61$455
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha38$384
Acetazolamide ErAcetazolamide12$281
Doxycycline Hyclate11$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$13$2,99219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in San Luis Obispo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →